Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas J Louie

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 16, 2006
Treatment of first recurrences of Clostridium difficile-associated disease: waiting for new treatment optionsThomas J Louie
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|October 26, 2005
How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?Thomas J Louie
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|July 9, 2004
Clostridium difficile infection in hospitals: risk factors and responsesThomas J Louie, Jon Meddings
JAMA|March 28, 2023
Extended Follow-up of Microbiome Therapeutic SER-109 for Recurrent Clostridioides difficile Infection-ReplyStuart H Cohen, Thomas J Louie, Barbara H McGovern
Antimicrobial Agents and Chemotherapy|October 29, 2008
OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infectionThomas J Louie, Judy Emery, Walter Krulicki, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 4, 2012
Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infectionPamela Sears, Derrick W Crook, Thomas J Louie, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2012
Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrheaStuart Johnson, Dale N Gerding, Thomas J Louie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 4, 2012
Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDIThomas J Louie, Kris Cannon, Brendan Byrne, et al.
The Journal of Infectious Diseases|February 20, 2013
A potential new tool for managing Clostridium difficile infectionGlen D Armstrong, Dylan R Pillai, Thomas J Louie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 4, 2012
Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycinOliver A Cornely, Mark A Miller, Thomas J Louie, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 16, 2006
Treatment of first recurrences of Clostridium difficile-associated disease: waiting for new treatment optionsThomas J Louie
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|October 26, 2005
How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?Thomas J Louie
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|July 9, 2004
Clostridium difficile infection in hospitals: risk factors and responsesThomas J Louie, Jon Meddings
JAMA|March 28, 2023
Extended Follow-up of Microbiome Therapeutic SER-109 for Recurrent Clostridioides difficile Infection-ReplyStuart H Cohen, Thomas J Louie, Barbara H McGovern
Antimicrobial Agents and Chemotherapy|October 29, 2008
OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infectionThomas J Louie, Judy Emery, Walter Krulicki, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 4, 2012
Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infectionPamela Sears, Derrick W Crook, Thomas J Louie, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2012
Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrheaStuart Johnson, Dale N Gerding, Thomas J Louie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 4, 2012
Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDIThomas J Louie, Kris Cannon, Brendan Byrne, et al.
The Journal of Infectious Diseases|February 20, 2013
A potential new tool for managing Clostridium difficile infectionGlen D Armstrong, Dylan R Pillai, Thomas J Louie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 4, 2012
Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycinOliver A Cornely, Mark A Miller, Thomas J Louie, et al.
Pageof 4